Effectiveness of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ.

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

Royalty Pharma will provide up to $1.25 billion in exchange for a synthetic royalty on annual worldwide net sales of daraxonrasib (and zoldonrasib if approved in an overlapping daraxonrasib indication ...

The lawmakers accuse Pfizer, Merck, J&J, AbbVie and Amgen of paying little to nothing in federal taxes despite generating billions of dollars annually.

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.